Group items tagged

The Small Business Liability Relief and Brownfields Revitalization Act ("Brownfields Law", P.L. 107-118) requires the U.S. Environmental Protection Agency (EPA) to publish guidance to assist applicants in preparing proposals for grants to assess and clean up brownfield sites. EPA's Brownfields Program provides funds to empower states, communities, tribes, and nonprofits to prevent, inventory, assess, clean up, and reuse brownfield sites. EPA provides brownfields funding for three types of grants: 1. Brownfields Assessment Grants - provides funds to inventory, characterize, assess, and conduct planning (including cleanup planning) and community involvement related to brownfield sites. 2. Brownfields Revolving Loan Fund (RLF) Grants - provides funds for a grant recipient to capitalize a revolving fund and to make loans and provide subgrants to conduct cleanup activities at brownfield sites. 3. Brownfields Cleanup Grants - provides funds to conduct cleanup activities at a specific brownfield site owned by the applicant. Under these guidelines, EPA is seeking proposals for Assessment Grants only. If you are interested in requesting funding for Cleanup Grants, please refer to announcement EPA-OSWER-OBLR-14-08 (Cleanup Grant guidelines) posted separately on www.grants.gov and www.epa.gov/brownfields. Note: A solicitation for new Revolving Loan Fund Grants will not be issued in FY15. EPA expects to solicit requests from existing, high performing RLF grantees 2 through a Federal Register notice for supplemental RLF funding in early 2015.

The Small Business Liability Relief and Brownfields Revitalization Act ("Brownfields Law", P.L. 107-118) requires the U.S. Environmental Protection Agency (EPA) to publish guidance for grants to assess and clean up brownfield sites. EPA's Brownfields Program provides funds to empower states, communities, tribes, and nonprofits to prevent, inventory, assess, clean up, and reuse brownfield sites. Under these guidelines, EPA is seeking proposals for Revolving Loan Fund Grants only. If you are interested in requesting funding for Assessment Grants and/or Cleanup Grants, please refer to announcement EPA-OLEM-OBLR-17-07 (Assessment Grant Guidelines) or EPA-OLEM-OBLR-17-09 (Cleanup Grant Guidelines) posted separately on www.grants.gov and www.epa.gov/brownfields/apply-brownfields-grant-funding. Also listed under assessment grants.

The John Z. Duling Grant Program was established and funded by a bequest from the estate of John Z. Duling of Indiana, a strong advocate of research who in 1972 proposed the establishment of the ISA Research Trust. The goal of this program is to provide start-up or seed funding to support innovative research and technology transfer projects that have the potential of benefiting the everyday work of arborists. John Z. Duling Grants may be used to support exploratory work in the early stages of untested, but potentially transformative, research ideas and approaches. Examples may include application of new approaches to research questions, or application of new expertise involving novel disciplinary or interdisciplinary perspectives. Projects are expected to be completed within one to three years with a maximum grant award of $25,000. No project may receive more than one award from this program. Due to the similarity of the Jack Kimmel International Grant and John Z. Duling Grant, applicants may submit to only one of these programs per annual project funding cycle. Note Well:  In 2020, TREE Fund's John Z. Duling Grant program will be focused specifically on urban forest management. Suggested areas of inquiry are (but are not limited to): Inventory and/or resource assessment; Development of management guidelines; Establishment, quantification and/or maintenance of ecosystem services; Pest/pathogen management; Assessing/maximizing returns on investments in urban forests;

Applicants for the funds may be students or faculty. The project, program, or entrepreneurial idea must be created by, led by or benefit women. Grants are awarded in values of $2500 to $20,000. While we prefer the base grant to be $5,000, we are considering a limited number of $2500 which will be required to show high impact. These applicants will be considered on a case-by-case basis. The grants must be submitted online via the link below and must include a 2-minute video. Applicants will be narrowed to a pool of 10-15 finalists by our M.I.A.M.I. WOMEN Grants Committee. This committee will review applications; contact applicants if additional information is required, and present the finalists to the M.I.A.M.I. WOMEN Steering Committee and Development Staff. Grant deadline for this year is Feb. 9, 2018. These finalists will perform in a fast-pitch style Hawk Tank event on April 11, 2018. Finalists will be offered fast-pitch training courtesy of the Farmers School of Business - school of Entrepreneurship, and will receive coaching and support. They will then pitch their idea in 5 minutes or less on April 11, 2018 at the event. Giving Circle members are the voters who will determine winners. Absentee voters will be given the option to vote online. Winners will be announced that night or the next day at the Symposium, to be determined.

The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to-Phase II SBIR grant mechanism.  Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, R&D that is characteristic of Phase-I (R43) SBIR projects.  The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type R&D, to expand R&D opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.   

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes.  Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them.  Responsive grant applications must involve a formal collaboration with a healthcare provider or other healthcare organization serving one or more health disparity populations during Phase I and Phase II.

The RBOG program promotes sustainable economic development in rural communities with exceptional needs through provision of training and technical assistance for business development, entrepreneurs, and economic development officials and to assist with economic development planning. Rural Development is participating in the Investing in Manufacturing Communities Partnership (IMCP), which is a new Administration-wide initiative that will accelerate the resurgence of manufacturing and help cultivate an environment for businesses to create well-paying manufacturing jobs in regions across the country. The IMCP is designed to reward communities that demonstrate best practices in attracting and expanding manufacturing by using long-term planning that integrates targeted investments in workforce training, infrastructure, research, and other key assets. The IMCP is being initiated in FY 2013 as EDA, USDA, SBA and EPA each provide funding for regional implementation strategy grants.

This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to develop or improve technologies for obtaining, characterizing and testing animal and human stem cells and their derivatives as models for stem cell-based regenerative medicine using animal models. The program is intended to support projects devoted to the creation of informative animal models for regenerative medicine, which will facilitate testing the safety and therapeutic potential of animal and human stem cells and their derivatives for pre-clinical evaluation. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cells and their derivatives, including production, characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications. The ultimate objective of these efforts should be to provide commercial products and technologies that can help develop future clinical therapies.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop or improve technologies for obtaining, characterizing and testing animal and human stem cells and their derivatives as models for stem cell-based regenerative medicine using animal models. The program is intended to support projects devoted to the creation of informative animal models for regenerative medicine, which will facilitate testing the safety and therapeutic potential of animal and human stem cells and their derivatives for pre-clinical evaluation. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cells and their derivatives, including production, characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications. The ultimate objective of these efforts should be to provide commercial products and technologies that can help develop future clinical therapies.

This Funding Opportunity Announcement (FOA) reissued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the Administration for Children and Families (ACF) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, FDA or ACF awarding components identified in this FOA are encourag

This Funding Opportunity Announcement (FOA) encourages Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to address problems associated with the methods of collection, bioassay, isolation, purification, de-replication, yield, and supply that hamper the full utilization of natural products.

REAP provides grants to agricultural producers and rural small businesses to conduct feasibility study for a renewable energy system as well as to purchase and install renewable energy systems or make energy efficiency improvements. The program is designed to help agricultural producers and rural small businesses reduce energy costs and consumption and help meet the Nation's critical energy needs.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) Fast Track grant applications that propose to test and/or validate novel, state-of-the-art candidate biomarker platforms for predicting the onset and progression of inflammatory diseases of interest to the NIAMS and for determining the pharmacodynamics, safety and/or efficacy of therapeutic agents targeting those diseases.

The National Human Genome Research Institute (NHGRI) solicits SBIR (R43/R44) grant applications to develop novel technologies that will enable extremely low-cost, high quality DNA sequencing. The goal of this initiative is to reduce the cost of sequencing a mammalian-sized genome to approximately $1000. Applicants may propose to develop full-scale sequencing systems or to investigate challenges underlying key system components. Exploration of methods other than those currently being pursued as potential $1,000 genome technologies is encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop novel technologies to expand the capability for molecular analyses of banked frozen or formalin-fixed, paraffin-embedded tissues. In addition, there is a need for improved tissue fixatives and preservation methods that maintain histologic features while preserving high quality DNA, RNA, protein and small molecules in archived tissue from rodent and human studies.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes. Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations.

WIIN addresses, supports and improves America's drinking water infrastructure.  Included in the WIIN Act are three new drinking water grants that promote public health and the protection of the environment.  As part of the grant, the EPA will award approximately $1.2 million for fiscal year 2018 to support lead testing in drinking water at tribal schools and child care facilities. 

The National Institutes of Health (NIH) hereby notify Small Business Concerns (SBCs) holding Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research or in the SBIR program. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project.